The nepafenac punctal plug drug delivery system (PPDS) was found to be safe and effective for reducing pain and inflammation associated with cataract surgery in a phase II FDA study.
A novel punctal plug drug delivery system (PPDS) was found to be safe and effective for reducing pain and inflammation associated with cataract surgery in a phase II FDA study.
Compared with placebo-treated controls, patients receiving the nepafenac PPDS also experienced fewer adverse events and superior visual acuity outcomes, said Eric D. Donnenfeld, MD.
“Inflammation is common following cataract surgery, and it can lead to serious complications if left untreated. Results of the ESCRS prospective PREMED study showed that NSAIDs were more important than corticosteroids for reducing the risk of CME,” said Dr. Donnenfeld, founder, Ophthalmic Consultants of Long Island, Garden City, NY, and clinical professor of ophthalmology, New York University, New York.
“The nepafenac PPDS simplifies medical management for the elderly patient population and resolves the problems associated with the use of topical medication,” he said. “It demonstrated unprecedented efficacy in reducing pain and inflammation after cataract surgery in the phase II study. If the outcomes are confirmed in phase III trials, the nepafenac PPDS may effectively replace topical NSAID drops in cataract surgery.”
Eric D. Donnenfeld, MD
This article is based on a presentation given by Dr. Donnenfeld at the 2019 ASCRS Symposium. Dr. Donnenfeld is a consultant to Mati Therapeutics and to other companies that are developing or market ophthalmic anti-inflammatory products.